Surrogate end points in oncology: aligning drug development incentives and patient needs.
Saved in:
| Title: | Surrogate end points in oncology: aligning drug development incentives and patient needs. |
|---|---|
| Authors: | Vogel M; John F. Kennedy School of Government, Harvard University, Cambridge, MA, USA. mvogel@hks.harvard.edu., Yaeger R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Stewart DJ; Division of Medical Oncology, University of Ottawa, Ottawa, Ontario, Canada., Subbiah V; Early Phase Drug Development Program, Sarah Cannon Research Institute, Nashville, TN, USA., David FS; Department of Biology, Tufts University, Medford, MA, USA.; Pharmagellan LLC, Milton, MA, USA. |
| Source: | Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2025 Aug; Vol. 22 (8), pp. 617-618. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500077 Publication Model: Print Cited Medium: Internet ISSN: 1759-4782 (Electronic) Linking ISSN: 17594774 NLM ISO Abbreviation: Nat Rev Clin Oncol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
